DPYD encodes dihydropyrimidine dehydrogenase (DPD), the rate-limiting enzyme¹¹ rate-limiting enzyme
DPD catabolizes 80-90% of administered 5-fluorouracil into inactive metabolites, preventing toxic accumulation that metabolises fluoropyrimidine chemotherapy drugs. DPYD*13 (c.1679T>G, p.Ile560Ser) is a rare missense variant that produces an essentially non-functional enzyme — first described in patients presenting with life-threatening 5-fluorouracil toxicity. It is one of only four DPYD variants that CPIC classifies as clinically actionable²² CPIC classifies as clinically actionable
The other three are DPYD*2A/rs3918290, c.2846A>T/rs67376798, and the HapB3 haplotype tagged by rs75017182/rs56038477 and that the European Medicines Agency mandates testing for before fluoropyrimidine-based cancer treatment.

The Mechanism

The *13 variant is a thymine-to-guanine substitution at position 1679 of the DPYD coding sequence, which replaces isoleucine with serine at amino acid 560³³ isoleucine with serine at amino acid 560
I560S — a non-conservative substitution swapping a hydrophobic branched-chain residue for a small polar one, located in a highly conserved catalytic region of the DPD protein. Because DPYD sits on the minus strand of chromosome 1, the coding-strand T>G change appears as an A>C substitution at position 97,515,787 of the GRCh38 plus strand — which is how genome sequencing files report it.

Isoleucine 560 sits in one of the enzyme's structural domains required for proper protein folding and substrate binding; structural modelling predicts substantial disruption of the local hydrophobic core. Functional assays consistently place I560S at less than 25% of wild-type DPD activity, and CPIC treats *13 as a no-function allele equivalent in consequence to DPYD*2A⁴⁴ no-function allele equivalent in consequence to DPYD*2A
activity score 0, identical to *2A and strictly worse than the decreased-function c.2846A>T and HapB3 variants which score 0.5. That makes heterozygotes effectively 50% DPD-deficient and homozygotes (extraordinarily rare, roughly 1 in a million) functionally DPD-null.

The Evidence

DPYD*13 was first identified in the early 2000s through case reports of patients who developed life-threatening toxicity after receiving standard-dose 5-fluorouracil or capecitabine. Subsequent functional work and in silico modelling consistently place *13 in the same no-function category as *2A, and the 2017 CPIC guideline⁵⁵ 2017 CPIC guideline
Amstutz et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update. Clin Pharmacol Ther. 2018 assigns it an activity score of 0 — identical to *2A and strictly worse than the decreased-function c.2846A>T and HapB3 variants, which score 0.5.

The landmark prospective Alpe-DPD study⁶⁶ landmark prospective Alpe-DPD study
Henricks et al. Lancet Oncol 2018, a Dutch multicentre trial that pre-genotyped 1,103 cancer patients before fluoropyrimidine exposure and applied genotype-guided dose reductions included DPYD*13 carriers alongside *2A, c.2846A>T, and HapB3 carriers. With a 50% initial dose reduction, severe toxicity in no-function variant carriers dropped from the 73-77% rate observed historically under standard dosing toward approximately 31% — essentially matching non-carrier background risk. Critically, matched-pair analyses showed no loss of overall survival or progression-free survival in dose-reduced carriers. A 2021 meta-analysis⁷⁷ 2021 meta-analysis
Sharma et al. Pathogenic DPYD Variants and Treatment-Related Mortality in Patients Receiving Fluoropyrimidine Chemotherapy: A Systematic Review and Meta-Analysis. The Oncologist 2021 confirmed that carriers of DPYD no-function alleles — *2A and *13 combined — have a 25.6-fold higher risk of treatment-related death than non-carriers when given standard doses, and that pre-emptive genotype-guided dose reduction eliminates this excess mortality.

European-scale implementation data from the 2023 PhotoDPYD study of 8,054 Spanish cancer patients⁸⁸ 2023 PhotoDPYD study of 8,054 Spanish cancer patients
The largest prospective DPYD screening cohort to date, covering the four-variant panel mandated by the European Medicines Agency across a national oncology network found DPYD*13 at roughly 0.1% allele frequency in Spain, consistent with gnomAD v4 data showing ~0.085% non-Finnish European allele frequency (996 carriers among 1.18 million alleles sequenced). The variant is essentially absent in East Asian, South Asian, and Latino populations, very rare in African ancestry (~0.015%), and has only been documented in a handful of homozygous cases worldwide.

Practical Implications

If you carry one copy of DPYD*13, you have approximately 50% of normal DPD enzyme activity and are at dramatically elevated risk of severe, potentially fatal toxicity from fluoropyrimidine chemotherapy. These drugs — 5-fluorouracil (5-FU), capecitabine (Xeloda), and tegafur⁹⁹ 5-fluorouracil (5-FU), capecitabine (Xeloda), and tegafur
Backbone treatments for colorectal, breast, gastric, pancreatic, head-and-neck, and several other cancers — must be started at 50% of the standard dose, exactly as with DPYD*2A carriers. This is a CPIC Level A recommendation with the highest strength of evidence. Your oncologist should then use therapeutic drug monitoring (plasma 5-FU concentration measurements) to cautiously titrate the dose upward based on tolerability, typically reaching 65-80% of standard by the second or third cycle.

If you are homozygous for 13 or compound heterozygous with another no-function DPYD variant (*2A or a second *13 allele), fluoropyrimidines are **absolutely contraindicated*. The FDA label for fluorouracil¹⁰¹⁰ The FDA label for fluorouracil
"No dose of fluorouracil has been proven safe in individuals with absent DPD activity" explicitly states no dose has been proven safe in DPD-null individuals, and multiple fatal outcomes have been documented in these genotypes. Your oncology team must choose an alternative regimen: oxaliplatin- or irinotecan-based chemotherapy for colorectal cancer, anthracycline/taxane protocols for breast cancer, gemcitabine-based regimens for pancreatic cancer, and so on. Uridine triacetate¹¹¹¹ Uridine triacetate
Vistogard — an FDA-approved pyrimidine-analog antidote that bypasses DPD by flooding the system with competing uridine nucleotides is the FDA-approved emergency antidote for life-threatening fluoropyrimidine overdose and must be given within 96 hours of exposure; its existence does not justify exposing known DPD-deficient patients to these drugs in the first place.

Testing DPYD before starting fluoropyrimidine therapy is now mandatory in much of Europe, standard of care in the UK NHS, and cost-effective by every published analysis¹²¹² cost-effective by every published analysis
Preventing one case of severe toxicity saves $155,000-180,000 in hospital and rescue costs, versus ~$160-250 for targeted DPYD panel genotyping. Most commercial DPYD panels test the four CPIC priority variants together — *2A, *13, c.2846A>T, and HapB3 — so a result for one almost always comes with results for the others. If your oncologist has not ordered DPYD testing before prescribing a fluoropyrimidine, request it explicitly and wait for the result before starting treatment.

Interactions

DPYD*13 is one of four clinically actionable DPYD variants that together define DPD metabolizer status in the CPIC activity-score system¹³¹³ CPIC activity-score system
Activity score 2.0 = normal metaboliser; 1.0-1.5 = intermediate metaboliser (heterozygous for a no-function or decreased-function allele); 0-0.5 = poor metaboliser (homozygous or compound heterozygous for actionable variants). 13 and *2A are **no-function* alleles (activity contribution: 0), whereas c.2846A>T and HapB3 are decreased-function alleles (activity contribution: 0.5). Compound heterozygotes — carrying *13 alongside *2A, c.2846A>T, or HapB3 — drop to activity scores of 0-0.5 and are typically treated as poor metabolizers requiring fluoropyrimidine avoidance rather than dose reduction. These combinations are extraordinarily rare but have been documented in case series, with consistently severe outcomes under standard dosing.

Because the four-variant DPYD panel only captures roughly 20-30% of patients who ultimately develop severe fluoropyrimidine toxicity¹⁴¹⁴ roughly 20-30% of patients who ultimately develop severe fluoropyrimidine toxicity
The remaining 70-80% of severe toxicity cases are driven by rare DPYD variants not on the panel, variants in other pyrimidine-pathway genes (TYMS, MTHFR), drug interactions, and non-genetic factors, a normal DPYD*13 result does not eliminate the need for careful clinical monitoring during fluoropyrimidine chemotherapy. Conversely, a *13 carrier result is enormously valuable precisely because it identifies patients for whom the toxicity risk would otherwise be missed. Some academic centres now also measure dihydrouracil/uracil ratio in plasma (a direct biomarker of DPD activity) as a complement to genotyping.

First-degree relatives of *13 carriers have a 50% prior probability of carrying the variant themselves and should be offered DPYD panel testing if they ever face fluoropyrimidine-based cancer treatment. Because *13 is so rare, family members are often the only other documented carriers in a given clinical setting.

Most people think of motion sickness as a minor inconvenience. Genetics says otherwise. In 2015, the first genome-wide association study of motion sickness — analyzing 80,494 participants¹¹ 80,494 participants
Hromatka et al. Genetic variants associated with motion sickness point to roles for inner ear development, neurological processes and glucose homeostasis. Human Mol Genet, 2015 — found 35 SNPs reaching genome-wide significance, implicating genes involved in inner ear development, nervous system function, and vestibular signaling. rs61759167 was one of the strongest hits, with a p-value of 4×10⁻¹³. The same T allele was independently associated with antimigraine medication use (a proxy for migraine diagnosis) at P=8×10⁻¹¹ — making this variant one of the clearest demonstrations that motion sickness and migraine share overlapping genetic architecture.

The Mechanism

rs61759167 sits in the first intron of PRDM16²² PRDM16
PR/SET Domain 16 — a zinc-finger transcription factor that acts as a master switch for multiple cell fate decisions, most notably the conversion of progenitor cells into brown/beige adipocytes and, during development, specification of neural crest cells at chromosome 1p36.32. This intronic region likely contains regulatory elements that modulate PRDM16 expression levels in relevant tissue contexts.

The neurovascular connection is plausible from multiple angles. PRDM16 is expressed in the developing inner ear and neural crest-derived structures including those of the peripheral nervous system. The perivascular fat surrounding cranial blood vessels also expresses PRDM16, and loss of PRDM16 function in adipocytes triggers vascular remodeling and increased vascular reactivity — a mechanism directly relevant to migraine, which is fundamentally a neurovascular disorder. The shared signal for both motion sickness and migraine at this locus strongly implies that PRDM16 influences a shared biological substrate: perhaps vestibular sensitivity, perhaps trigeminovascular reactivity, or both.

rs61759167 is located approximately 8 kb from rs2651899, the well-established PRDM16 migraine locus identified in the original Women's Genome Health Study GWAS³³ GWAS
Chasman et al. Genome-wide association study reveals three susceptibility loci for common migraine. Nat Genet, 2011. Whether rs61759167 and rs2651899 are in strong linkage disequilibrium⁴⁴ linkage disequilibrium
LD — the tendency for nearby variants to be inherited together — meaning they may tag the same causal variant, or they may represent independent signals in a complex regulatory region within PRDM16 intron 1 has not been definitively established.

The Evidence

The Hromatka 2015 GWAS⁵⁵ Hromatka 2015 GWAS
Hromatka et al. Genetic variants associated with motion sickness point to roles for inner ear development, neurological processes and glucose homeostasis remains the only large-scale genetic study of motion sickness. At 80,494 participants it is among the largest single-trait GWAS ever conducted at the time of publication, giving strong statistical confidence to the rs61759167 association (P=4×10⁻¹³, far exceeding the 5×10⁻⁸ genome-wide significance threshold). The study confirmed that motion sickness shares genetic architecture with migraines, postoperative nausea, vertigo, and altitude sickness, and noted sex-specific effects with women experiencing up to three times stronger genetic effects than men.

The PRDM16 migraine association at the neighboring rs2651899 locus is independently replicated across populations. A meta-analysis by Lee et al. 2020⁶⁶ meta-analysis by Lee et al. 2020
Lee et al. Association of rs2651899 Polymorphism in PRDM16 and Common Migraine Subtypes. Headache, 2020 of six studies (2,853 cases, 9,319 controls) confirmed OR = 1.42 for migraine under a recessive model. These findings at the adjacent variant strengthen the biological case for PRDM16 intron 1 as a genuine migraine susceptibility region.

For magnesium as an intervention: a systematic review by von Luckner and Riederer 2018⁷⁷ systematic review by von Luckner and Riederer 2018
von Luckner, Riederer. Magnesium in Migraine Prophylaxis — Is There an Evidence-Based Rationale? Headache, 2018 analysed five randomised double-blind placebo-controlled trials and concluded that high-dose magnesium dicitrate 600 mg/day is Grade C (possibly effective) for migraine prevention, with one high-quality trial showing significant attack reduction.

Practical Actions

Carriers of the T allele — and especially TT homozygotes — face a dual vulnerability: heightened motion sickness susceptibility and elevated migraine risk. The practical implications are distinct:

For motion sickness, the genetic signal offers predictive utility. T carriers should plan seating strategies proactively (front seat in cars, forward-facing seats on trains, above-wing seats on aircraft, above-deck positions on boats) and consider first-line motion sickness interventions before exposure rather than reactively.

For migraine prevention, magnesium supplementation (400–600 mg/day as glycinate or dicitrate) has direct mechanistic rationale: magnesium deficiency lowers the threshold for cortical spreading depression (the electrophysiological event underlying migraine aura and believed to trigger the pain cascade), and serum/brain magnesium is consistently low during migraine attacks. Clinicians experienced in headache medicine often prescribe oral magnesium as first-line preventive therapy given its safety profile.

Carriers who develop both motion sickness and migraines — a co-occurrence this variant predicts — should be evaluated for vestibular migraine⁸⁸ vestibular migraine
a variant of migraine in which vestibular symptoms (dizziness, vertigo, imbalance) are the dominant feature rather than or in addition to headache; underdiagnosed and often misclassified as Ménière's disease, which is specifically linked to motion sensitivity and is treatable with standard migraine preventives.

Interactions

The nearest PRDM16 variant in the database, rs2651899, covers overlapping migraine biology from the same gene region. rs10166942 (TRPM8), another SNP from the Chasman 2011 migraine GWAS, represents an independent pathway (cold-sensing ion channel) that converges on similar neurovascular vulnerability. Carrying risk alleles at multiple migraine-associated loci (rs61759167, rs2651899, rs10166942) is expected to compound migraine susceptibility, though formal interaction studies for this specific combination have not been published.

The insulin gene (INS) on chromosome 11p15.5 controls more than blood sugar regulation. A polymorphic repeat region in its promoter — the Variable Number Tandem Repeat¹¹ Variable Number Tandem Repeat
A stretch of short DNA sequences repeated between 26 and ~200 times just upstream of the insulin coding region (VNTR) — determines how much insulin is expressed in the thymus, the organ that trains the immune system to ignore the body's own tissues. The rs689 A/T SNP is a tag variant in near-complete linkage disequilibrium²² linkage disequilibrium
LD means the A/T allele at rs689 reliably predicts which VNTR class a person carries, without sequencing the repeat itself with the VNTR class: the A allele marks the shorter Class I repeats (26–63 copies), and the T allele marks the longer Class III repeats (~140–210 copies). This single locus — IDDM2 — accounts for roughly 10% of the familial clustering of type 1 diabetes (T1D) and is the strongest non-HLA genetic risk factor for the disease.

The Mechanism

The rs689 A allele weakens the polypyrimidine tract³³ polypyrimidine tract
A pyrimidine-rich sequence just upstream of the intron 1 splice acceptor site that U2AF35 protein must bind to initiate splicing at the 3′ splice site of INS intron 1. In carriers of the A allele, intron 1 retention increases and proinsulin output drops — the INS transcript is less efficiently processed. In medullary thymic epithelial cells⁴⁴ medullary thymic epithelial cells
mTECs are the cells that present self-antigens including insulin to developing T cells; T cells that react too strongly are deleted — a process called central tolerance (mTECs), this reduced insulin expression means fewer insulin-reactive T cells are deleted during immune education. Cai et al.⁵⁵ Cai et al.
Cai CQ et al. Both polymorphic VNTR and AIRE modulate differential expression of insulin in human thymic epithelial cells. Diabetes, 2010 measured a threefold difference in thymic insulin mRNA between Class III and Class I carriers in an AIRE-dependent manner. The surviving auto-reactive T cells can later reach the pancreas and destroy insulin-producing beta cells.

The Evidence

The most direct evidence comes from Kralovicova & Vorechovsky⁶⁶ Kralovicova & Vorechovsky
Kralovicova J, Vorechovsky I. Allele-specific recognition of the 3′ splice site of INS intron 1. Hum Genet, 2010, who showed that introducing the A allele into a protective Class III haplotype was sufficient to reduce proinsulin levels to those of a risk Class I construct. This positions rs689 — not the VNTR repeat count itself — as the functional effector⁷⁷ functional effector
Earlier models assumed the VNTR repeat length was the causal element; the 2010 work demonstrated the flanking SNPs controlling splicing are the true functional variants.

Fan et al.⁸⁸ Fan et al.
Fan Y et al. Thymus-specific deletion of insulin induces autoimmune diabetes. EMBO J, 2009 deleted insulin expression specifically in mTECs in mice and found 100% diabetes penetrance within 3 weeks postnatal — the most direct demonstration that thymic insulin is required for central tolerance to insulin-producing beta cells.

GWAS evidence is exceptionally strong: the GWAS Catalog records associations with T1D at p = 5 × 10⁻¹⁹⁶ for the A allele. The protective T allele (Class III) carries an OR of approximately 0.45 for T1D (OR ≈ 2.21 per T allele for protection in one large study), with risk frequency of the A allele at ~28% in Europeans. In African populations the A allele is markedly more common (~76%), but HLA alleles dominant in T1D susceptibility are rarer in African-ancestry populations, so the overall T1D rate does not simply track the A allele frequency.

Practical Actions

The INS VNTR locus primarily informs T1D risk stratification, not treatment. There are no approved interventions that modify VNTR function. For AA homozygotes, the main value is awareness: earlier monitoring for T1D-associated autoantibodies (IAA, GADA, IA-2A, ZnT8A) substantially improves the chance of catching pre-symptomatic T1D before diabetic ketoacidosis occurs. At-risk individuals can also evaluate eligibility for T1D prevention trials such as teplizumab (anti-CD3 antibody), which has FDA approval to delay T1D onset in at-risk individuals with 2+ autoantibodies.

Interactions

The IDDM2 effect is additive with HLA class II risk alleles. Individuals carrying both the AA genotype here and high-risk HLA-DR3/DR4-DQ8 haplotypes have substantially higher lifetime T1D risk than either locus predicts alone. rs3842753 (the −23HphI variant, also in the INS 3′ UTR) is a second INS tag SNP in high LD with rs689 and is often co-analyzed. rs7903146 (TCF7L2) primarily affects T2D risk through beta-cell mass, a distinct mechanism from the central tolerance pathway here.

The AHCY gene produces S-adenosylhomocysteine hydrolase, the only mammalian enzyme capable of converting S-adenosylhomocysteine (SAH) to homocysteine and adenosine. This seemingly simple reaction is critical: SAH is a potent inhibitor of methyltransferases¹¹ SAH is a potent inhibitor of methyltransferases
SAH inhibits hundreds of methylation reactions throughout the body, affecting DNA methylation, neurotransmitter synthesis, and detoxification. When AHCY activity is reduced, SAH accumulates, methylation grinds to a halt, and cellular dysfunction follows.

The rs819147 variant appears to influence AHCY expression or enzyme efficiency, though the exact mechanism remains under investigation. Unlike the rare pathogenic AHCY mutations that cause severe hypermethioninemia²² hypermethioninemia
A rare metabolic disorder with developmental delays, elevated methionine and SAH, caused by profound AHCY deficiency, rs819147 is a common regulatory variant found in roughly 20% of most populations. Its effects are subtle but meaningful for methylation balance.

The Mechanism

AHCY sits at a critical juncture in the methylation cycle. After SAM (S-adenosylmethionine)³³ SAM (S-adenosylmethionine)
The universal methyl donor, used in hundreds of methylation reactions donates a methyl group, it becomes SAH. AHCY immediately hydrolyzes SAH to homocysteine and adenosine, maintaining the SAM/SAH ratio — the "methylation potential" of the cell. A high SAM/SAH ratio means robust methylation capacity; a low ratio means impaired methylation.

The C allele at rs819147 may reduce AHCY expression or stability, leading to slower SAH clearance. SAH accumulates, competitively inhibiting methyltransferases and reducing the effective pool of SAM. The result: impaired methylation of DNA, histones, proteins, neurotransmitters, and phospholipids. Homocysteine levels may or may not rise — paradoxically, reduced AHCY activity can lower homocysteine by slowing its production from SAH, though this is not protective if SAH accumulates. The T allele is the common (wild-type) allele found in ~72% of alleles globally and ~89% in Europeans.

The Evidence

Research on rs819147 is less extensive than for coding variants, but its inclusion in methylation pathway testing panels⁴⁴ methylation pathway testing panels
Commercial methylation panels test AHCY alongside MTHFR, MTR, MTRR, and COMT reflects clinical interest. A 2004 study in European Journal of Human Genetics⁵⁵ 2004 study in European Journal of Human Genetics
Gellekink et al. examined AHCY genetic variation and homocysteine found that common AHCY variants influence homocysteine levels and venous thrombosis risk, though specific rsids were not always detailed.

More broadly, AHCY deficiency studies⁶⁶ AHCY deficiency studies
Rare complete deficiency causes hypermethioninemia, elevated SAH, developmental delays demonstrate the enzyme's critical role. Even partial reductions in activity, as seen with common variants, can shift methylation balance. A 2021 review in Frontiers in Cell and Developmental Biology⁷⁷ 2021 review in Frontiers in Cell and Developmental Biology
AHCY is recruited to chromatin during replication and transcription to meet local methylation demands noted that AHCY is actively recruited to sites of high methylation demand, suggesting that reduced activity could disproportionately affect rapidly dividing or transcriptionally active cells.

Cardiovascular research⁸⁸ Cardiovascular research
Elevated SAH and homocysteine independently predict cardiovascular disease risk shows that both elevated homocysteine and elevated SAH are independent cardiovascular risk factors. The T allele at rs819147, by potentially raising SAH, may contribute modestly to cardiovascular and inflammatory risk, though large-scale GWAS have not isolated this variant as a major risk locus. Evidence level: moderate, based on mechanistic plausibility and smaller genetic association studies.

Practical Implications

For CC carriers, supporting the methylation cycle through diet and targeted supplementation is the most direct intervention. The goal is to reduce SAH accumulation and maintain methylation capacity despite reduced AHCY efficiency.

Betaine (trimethylglycine) is particularly valuable. It donates a methyl group to remethylate homocysteine back to methionine via BHMT, bypassing the folate-dependent pathway and reducing the burden on AHCY to clear SAH. Methylfolate (5-MTHF) and methylcobalamin support the MTR/MTRR pathway, also remethylating homocysteine and maintaining methionine (and thus SAM) production.

Vitamin B2 (riboflavin) and B6 (pyridoxal-5-phosphate) are cofactors for methylation enzymes. Adequate choline supports phosphatidylcholine synthesis and reduces SAM demand. Antioxidants like vitamin C and E may protect AHCY from oxidative inactivation — AHCY is sensitive to oxidative stress and heavy metals⁹⁹ AHCY is sensitive to oxidative stress and heavy metals
Environmental exposures reduce AHCY activity independent of genetics, compounding genetic effects.

Avoiding excess methionine from supplements is prudent; high methionine intake increases SAM production, and if AHCY can't keep up with SAH clearance, methylation inhibition worsens. Focus on balanced protein intake from whole foods.

Monitoring homocysteine and, if available, SAM/SAH ratios provides direct feedback on methylation status. Elevated homocysteine or a low SAM/SAH ratio indicates impaired methylation capacity requiring intervention.

Interactions

AHCY does not work in isolation — it's part of the tightly integrated methylation cycle. Variants in MTHFR (rs1801133, rs1801131) reduce methylfolate production, limiting homocysteine remethylation and increasing the SAH burden on AHCY. Variants in MTR and MTRR slow homocysteine remethylation, similarly increasing SAH. BHMT variants reduce betaine-dependent remethylation, again increasing reliance on AHCY to clear SAH.

The combination of AHCY rs819147 CC with MTHFR C677T TT is particularly challenging: reduced methylfolate production from MTHFR and impaired SAH clearance from AHCY create a methylation bottleneck. Such individuals may have elevated SAH, elevated homocysteine, and impaired methylation despite adequate B-vitamin intake. Aggressive methylfolate and betaine supplementation, along with monitoring, is warranted.

Similarly, CBS upregulations (e.g., rs234706) shunt homocysteine toward the transsulfuration pathway, potentially lowering homocysteine but not addressing SAH accumulation. COMT variants affect catecholamine methylation; slow COMT (rs4680 AA) increases SAM demand, potentially worsening SAH accumulation if AHCY is impaired.

Note on allele frequencies: The C allele frequency varies dramatically by ancestry — about 11% in Europeans but up to 70% in African populations — making this one of the most ancestry-variable methylation variants.

These multi-gene interactions underscore the value of comprehensive methylation pathway testing and personalized nutrient therapy.

Inside every cell, the circadian clock ticks through a 24-hour negative feedback loop: the CLOCK:BMAL1 protein complex drives expression of PER and CRY genes; PER and CRY proteins then feed back to inhibit CLOCK:BMAL1, completing one cycle. The speed of this loop — and therefore whether your internal day runs fast or slow — depends critically on how quickly CRY proteins are cleared. FBXL3 (F-box and leucine-rich repeat protein 3) is the molecular timer that sets this clearance rate. As the substrate- recognition subunit of the SCF^FBXL3 ubiquitin ligase complex¹¹ ubiquitin ligase complex
E3 ubiquitin ligases tag proteins with ubiquitin chains, marking them for destruction by the proteasome, FBXL3 directly binds CRY1 and CRY2 and marks them for proteasomal degradation. More FBXL3 activity → faster CRY turnover → shorter period; less activity → slower CRY turnover → longer period.

The variant rs9565309 (NC_000013.11:g.77002892T>C) sits in the 3' UTR region of the neighboring CLN5 gene and in the regulatory vicinity of FBXL3 on chromosome 13q22.3. It is a GWAS tag SNP — a marker in linkage disequilibrium with the causal variant(s) near or within FBXL3 — rather than the functional mutation itself. The C allele of this tag SNP is associated with increased morningness (earlier chronotype) preference, consistent with slightly enhanced FBXL3-mediated CRY clearance shortening the circadian period toward an earlier phase.

The Mechanism

Mouse genetics established the causal logic cleanly. Two independent loss-of-function alleles of Fbxl3 produce mice with dramatically lengthened circadian periods: the after-hours (Afh) Cys358Ser allele causes ~27-hour free-running rhythms²² the after-hours (Afh) Cys358Ser allele causes ~27-hour free-running rhythms
Godinho et al. Science 2007, and the Overtime (Ovtm) allele causes ~26-hour periods through CRY protein stabilization and global suppression of Per and Cry gene transcription³³ the Overtime (Ovtm) allele causes ~26-hour periods through CRY protein stabilization and global suppression of Per and Cry gene transcription
Siepka et al. Cell 2007. Silencing Fbxl3 in cell culture abolishes clock oscillation only in CRY-expressing cells⁴⁴ Silencing Fbxl3 in cell culture abolishes clock oscillation only in CRY-expressing cells
Busino et al. Science 2007, confirming CRY proteins are the obligate substrates. Translating this to humans: variants near FBXL3 that alter its expression or activity would be expected to shift chronotype in the direction predicted by the mouse data — higher FBXL3 activity tilting earlier, lower activity tilting later.

The rs9565309 C allele's OR of 1.19 for morningness is a subtle but consistent population-level effect. At the individual level, this variant nudges chronotype in the morning direction; it does not override the combined influence of PER3, CRY1, TIMELESS, and dozens of other clock gene variants. The T allele homozygote — the overwhelmingly common genotype (>92% of people) — carries the reference state: no added morningness push from this locus, and a slight statistical lean toward later sleep timing relative to C carriers.

The Evidence

The primary genetic association comes from Jones et al. (Nature Communications, 2019)⁵⁵ Jones et al. (Nature Communications, 2019)
PMID 30696823, a genome- wide association study of chronotype (self-reported morning vs. evening preference) in 697,828 UK Biobank and 23andMe participants — the largest chronotype GWAS published to date. The study increased the number of genome-wide significant chronotype loci from 24 to 351, with rs9565309 near FBXL3 among the hits at OR=1.19 for morningness. Overall, genes near these loci were enriched for circadian regulation pathways; the 5% of individuals carrying the most morningness alleles slept approximately 25 minutes earlier than the 5% carrying the fewest.

The mechanistic foundation rests on three landmark papers from 2007 that independently discovered FBXL3's role using classical forward genetics in mice: Godinho et al.⁶⁶ Godinho et al., Siepka et al.⁷⁷ Siepka et al., and Busino et al.⁸⁸ Busino et al.. Together they established that SCF^{FBXL3-mediated} CRY ubiquitination is a non- redundant step in mammalian circadian oscillation, and that its loss lengthens the free-running period by 2–3 hours. The human GWAS finding is biologically coherent with this mechanism.

The effect allele frequency varies substantially by ancestry: the C allele reaches ~12.8% in East Asian populations versus ~3.3% in Europeans and ~1.4% in Africans. This distribution makes the morningness association more common among East Asian carriers but does not alter the per-allele effect direction.

Practical Actions

The per-allele effect of rs9565309 is modest (OR=1.19 per C allele). T/T homozygotes have neither C allele and thus receive no morningness push from this locus — their sleep timing is governed by other genetic and behavioral factors. The most evidence-supported way to express whatever chronotype you have is through behavioral anchoring: a fixed wake time signals the suprachiasmatic nucleus to stabilize the free-running period against social and environmental drift. For the T/T majority, this is particularly important because without a morningness-promoting allele at this locus, circadian phase is more vulnerable to evening light exposure and irregular schedules.

Evening light management is the highest-leverage behavioral lever. Blue- wavelength light after sunset suppresses melatonin and phase-delays the circadian clock. Individuals without morningness-promoting variants benefit most from reducing this input. Amber-lens glasses or screen filters from approximately 2 hours before desired sleep time limit the phase-delaying signal without requiring lifestyle disruption.

Interactions

FBXL3 operates on CRY1 and CRY2 proteins. Variants in CRY1 and CRY2 themselves therefore interact with the FBXL3 pathway at the substrate level. The most clinically significant is rs184039278 (CRY1Δ11), a rare splice variant in CRY1 that produces a gain-of-function CRY1 protein resistant to normal turnover; even if FBXL3 activity is normal, this variant lengthens circadian period by ~30 minutes and drives Delayed Sleep Phase Disorder. Carriers of CRY1Δ11 who also carry the rs9565309 TT genotype would have both the CRY1 substrate problem and the absence of FBXL3-locus morningness support — potentially compounding the evening-phase tendency.

The PER3 VNTR polymorphism (rs57875989) and common variants in TIMELESS and CLOCK also contribute to chronotype independently. The rs9565309 locus is additive — its contribution to chronotype phenotype combines linearly with other genetic and behavioral influences rather than overriding them.

Your immune system's response to allergens, viruses, and skin-barrier disruptions begins with a deceptively simple signal: the release of thymic stromal lymphopoietin (TSLP)¹¹ thymic stromal lymphopoietin (TSLP)
An epithelial cytokine released by skin, airway, and gut lining cells in response to damage; triggers dendritic-cell-mediated Th2 inflammation from epithelial cells. TSLP is the "break-glass" alarm that tells the immune system an environmental threat has breached a body barrier. The rs3806933 variant sits directly in the promoter of the TSLP gene and determines how loudly that alarm rings.

This variant is distinct from the more widely studied rs1837253 (already on the platform). While rs1837253 is an upstream regulatory site that modulates baseline inducibility of TSLP across tissues, rs3806933 sits in the TSLP core promoter at position −847 and operates through a completely different mechanism. The two variants are not in strong linkage disequilibrium with each other, meaning they segregate independently in the population and can stack their effects.

The Mechanism

The rs3806933 C-to-T substitution at position −847 of the TSLP promoter does something structurally precise: it creates a de novo binding site for activating protein-1 (AP-1)²² creates a de novo binding site for activating protein-1 (AP-1)
AP-1 is a transcription factor complex (typically FOS-JUN heterodimers) activated by inflammatory cytokines, viral dsRNA, and stress signals — it amplifies gene transcription when bound to its target sequence. The C allele at this position does not support AP-1 binding; the T allele does. When an airway epithelial cell is stimulated by a viral signal (poly I:C, mimicking double-stranded RNA from respiratory infections), the T allele dramatically amplifies TSLP transcription through this new AP-1 site. The result is greater TSLP protein output during exactly the kind of infections that most commonly trigger asthma exacerbations.

The TSLP protein released then acts on plasmacytoid dendritic cells³³ plasmacytoid dendritic cells
Immune sentinels that, when activated by TSLP, express OX40L and prime naive T-cells to differentiate into Th2 cells rather than regulatory T-cells — the foundation of allergic inflammation, mast cells, and basophils — driving the full Th2 cascade of IL-4, IL-5, and IL-13 production that underlies asthma, allergic rhinitis, and atopic dermatitis. Critically, TSLP released from damaged skin also drives the atopic march: skin-barrier disruption → TSLP surge → airway Th2 sensitisation → asthma.

The Evidence

The functional and clinical evidence for rs3806933 rests on a multi-step foundation. The mechanistic work, published in the American Journal of Respiratory Cell and Molecular Biology⁴⁴ American Journal of Respiratory Cell and Molecular Biology, demonstrated the AP-1 binding gain-of-function directly: luciferase reporter assays in normal human bronchial epithelial cells showed that the T-allele promoter construct produced substantially more TSLP protein after poly(I:C) stimulation than the C-allele construct. This is a clean causal mechanism with experimental validation, not merely statistical association.

Clinically, the same study found the T allele associated with childhood atopic asthma (OR 1.25, 95% CI 1.07–1.47) and adult asthma (OR 1.37, 95% CI 1.12–1.67) in Japanese case-control cohorts totalling 1,280 cases and 1,214 controls. A subsequent meta-analysis pooling four independent studies⁵⁵ meta-analysis pooling four independent studies yielded a combined OR of 1.32 (95% CI 1.14–1.54, p<0.01) — consistent with a moderate but reproducible effect on asthma susceptibility. The variant's associations have been reported in Japanese, Korean, and Turkish populations, though effect sizes vary by ethnic background and disease phenotype.

The disease spectrum extends beyond the airways. A Taiwanese study of 470 Graves' disease patients found rs3806933 T-allele carriership associated with Graves' ophthalmopathy (GO)⁶⁶ associated with Graves' ophthalmopathy (GO) in female patients specifically (OR 1.79, 95% CI 1.16–2.77), consistent with TSLP's role in thyroid autoimmunity. In the 2017 Nature Genetics GWAS of 360,838 individuals⁷⁷ GWAS of 360,838 individuals analysing the shared genetic architecture of asthma, hay fever, and eczema, the TSLP locus was among the 136 independent signals identified — confirming that TSLP genetic variation contributes to the full allergic disease spectrum.

Pharmacogenomic relevance: Tezepelumab (Tezspire), the anti-TSLP monoclonal antibody approved by the FDA in 2021 for severe asthma, neutralises the TSLP protein directly. Individuals with the TT genotype — who overproduce TSLP through the AP-1 gain-of-function — represent the biological population with the strongest rationale for TSLP-targeted therapy. However, because tezepelumab works downstream of the variant (blocking the protein regardless of which genotype produced it), the drug's efficacy is not formally stratified by rs3806933 genotype in current labelling.

Practical Implications

Maintaining the skin and airway epithelial barrier is the most direct way to reduce TSLP release, regardless of genotype — but it is especially important for T allele carriers, who overproduce TSLP when epithelial cells are stressed. For TT carriers, the threshold at which infections and irritants trigger a Th2 storm is lower, making proactive barrier protection more consequential.

Skin barrier maintenance reduces TSLP release from keratinocytes. Emollient use in eczema-prone individuals has been shown in randomised trials to delay and reduce TSLP-driven atopic sensitisation. This mechanism is especially relevant for rs3806933 T carriers.

Interactions

rs3806933 and rs1837253 are independent TSLP locus signals that can compound. rs1837253 (already on the platform in the innate-immunity category) controls TSLP inducibility at a different regulatory element; rs3806933 controls AP-1-driven promoter activity. Carrying the high-TSLP genotype at both loci — CC at rs1837253 and TT at rs3806933 — would be expected to produce additive increases in TSLP output. rs2289276, a third TSLP promoter variant in high LD with rs3806933 (D′=0.97), is also in the related_snps list. TSLP pathway variants in downstream genes (IL7R, IL1RL1/ST2, TSLPR/CRLF2) can modulate the biological consequences of increased TSLP production.

CYP2E1 (cytochrome P450 2E1) is the liver enzyme responsible for metabolizing a diverse and clinically important set of substrates: acetaminophen¹¹ acetaminophen
paracetamol, converted by CYP2E1 to NAPQI — the toxic metabolite responsible for liver damage at overdose doses, ethanol at high concentrations, front-line anti-tuberculosis drugs including isoniazid, volatile anesthetics such as halothane and enflurane, and environmental toxins including benzene, styrene, and trichloroethylene. The CYP2E1*3 allele, defined by the rs55897648 G>A substitution at chromosome 10 position 133,537,760 (GRCh38), results in a valine-to-isoleucine change at position 389 (p.Val389Ile). Despite carrying a formal star allele designation in pharmacogenomics nomenclature, this is one of a handful of CYP2E1 coding variants that has been functionally characterised and found to have no meaningful impact on enzyme function.

The Mechanism

The Val389Ile substitution replaces a nonpolar [valine | a small nonpolar amino acid] with the structurally similar [isoleucine | also nonpolar, slightly bulkier side chain] at position 389, which lies in the enzyme's substrate-binding region but not within a catalytically critical residue. This conservative substitution apparently preserves the three-dimensional architecture of the active site. Hanioka et al. (2003)²² Hanioka et al. (2003)
Hanioka N et al. Functional characterization of three human cytochrome p450 2E1 variants with amino acid substitutions. Xenobiotica, 2003;33(6):575-86. expressed wild-type CYP2E1 and three variants — including CYP2E1.3 (Val389Ile) and CYP2E1.4 (Val179Ile) — as recombinant proteins and measured chlorzoxazone [6-hydroxylation | CYP2E1 activity is routinely measured using chlorzoxazone as a probe substrate — the enzyme converts it to 6-hydroxychlorzoxazone] as a functional readout. CYP2E1.3 showed protein levels and catalytic activity equivalent to wild-type; the variant that did show altered function (a roughly 2.7–3.0-fold higher catalytic efficiency) was the CYP2E1.2 (Arg76His) variant — a different SNP entirely.

The Evidence

The 2010 follow-up by the same group — Hanioka et al. (2010)³³ Hanioka et al. (2010)
Hanioka N et al. Functional characterization of human cytochrome P4502E1 allelic variants: in vitro metabolism of benzene and toluene by recombinant enzymes expressed in yeast cells. Arch Toxicol, 2010;84(5):363-71. — extended the analysis to environmental toxins, measuring benzene hydroxylation and toluene methylhydroxylation in a yeast expression system. The Km, Vmax, and intrinsic clearance values for CYP2E1*3 (Val389Ile) were comparable to wild-type across both substrates. This is notable because benzene bioactivation by CYP2E1 is linked to bone marrow toxicity and leukemia risk, yet CYP2E1*3 carriers do not appear to be at altered risk via this particular mechanism. Similarly, a Northern Spanish cohort study (Celorrio et al. 2012⁴⁴ (Celorrio et al. 2012
Celorrio D et al. A comparison of Val81Met and other polymorphisms of alcohol metabolising genes in patients and controls in Northern Spain. Alcohol, 2012;46(5):427-31.) typed rs55897648 alongside several other CYP2E1 and ALDH2 polymorphisms in alcohol-use cases and controls, finding no heterozygosity for this SNP in their 172-patient Spanish cohort — consistent with a European minor allele frequency of roughly 0.2%.

No published study has identified a significant clinical association between CYP2E1*3 and acetaminophen hepatotoxicity, alcohol-related liver disease, isoniazid adverse reactions, anesthetic toxicity, or cancer risk. Absence of evidence is not evidence of absence — the extreme rarity of the A allele (0.14–0.23% globally) means that adequately powered clinical studies have not been feasible. The functional null hypothesis (no effect) is supported by in vitro characterisation, but the variant cannot be considered functionally proven benign in a clinical sense.

Practical Actions

For the vast majority of carriers — who will have one copy of the A allele (GA genotype, approximately 0.23% prevalence in Europeans) — the in vitro data suggest no change in CYP2E1-mediated drug and toxin processing. Standard dosing for acetaminophen, standard monitoring during isoniazid therapy, and standard precautions around occupational chemical exposure all apply. The clinical guidance for CYP2E1-mediated risks in this individual rests more heavily on environmental and pharmacological inducers — alcohol (upregulates CYP2E1 protein), fasting/ketosis (stabilises CYP2E1), and concurrent substrate use — than on this specific missense variant.

The most clinically actionable CYP2E1 genetic variant is the synonymous exon-8 SNP [rs2515641 | CYP2E1 exon 8 synonymous variant that reduces mRNA and protein expression, associated with ~1.9-fold higher isoniazid adverse drug reaction risk], which demonstrably reduces CYP2E1 expression and has published clinical associations. Carriers of *3 who want a complete picture of their CYP2E1 pharmacogenomics should also check their rs2515641 result.

Interactions

Because CYP2E1*3 does not appear to alter enzymatic function, gene-gene interactions that depend on reduced CYP2E1 capacity (such as the NAT2 slow-acetylator / low CYP2E1 combination for isoniazid toxicity) are less likely to be relevant here. Chronic alcohol use, fasting, and obesity independently upregulate CYP2E1 protein regardless of genotype. Concurrent substrate competition (acetaminophen + isoniazid, or acetaminophen + ethanol) represents a pharmacological interaction that applies broadly to all CYP2E1 genotypes.

The PSEN2 gene encodes presenilin-2, one of four subunits of the γ-secretase complex¹¹ one of four subunits of the γ-secretase complex
The others are nicastrin, APH-1, and PEN-2; together they form an intramembrane aspartyl protease, the enzyme responsible for cleaving amyloid precursor protein (APP) within its transmembrane domain. Presenilin-2 forms the catalytic core of this complex, contributing the two catalytic aspartate residues essential for proteolysis. When γ-secretase cleaves APP, it generates amyloid-beta (Aβ) peptides of varying lengths — primarily Aβ40 (the most abundant form) and Aβ42 (the more fibrillogenic, plaque-forming form). Mutations in PSEN2 that shift cleavage toward longer, stickier Aβ42 and Aβ43 peptides are a direct molecular cause of early-onset familial Alzheimer's disease.

PSEN2 is the rarest of the three major familial AD genes (APP, PSEN1, PSEN2), accounting for fewer than 5% of all familial early-onset cases²² fewer than 5% of all familial early-onset cases
MedlinePlus reports at least 11 PSEN2 mutations causing early-onset AD; PSEN1 mutations account for the majority of genetic cases. A distinguishing feature of PSEN2-associated AD is variable and incomplete penetrance — unlike PSEN1 mutations, which are nearly fully penetrant, PSEN2 mutation carriers occasionally remain unaffected into their 80s, with population-level penetrance estimated at approximately 95% by age 80³³ 95% by age 80
Some PSEN2 mutation carriers have been documented as cognitively intact at ages well above the family mean, suggesting modifier loci or protective genetic factors. Age of onset is also broader than PSEN1, spanning roughly 40–75 years.

The N141Y variant (c.421A>T, p.Asn141Tyr, rs61761208) was first reported by Niu et al. in 2014⁴⁴ Niu et al. in 2014
Novel mutation in the PSEN2 gene (N141Y) associated with early-onset autosomal dominant Alzheimer's disease in a Chinese Han family. Neurobiol Aging, 2014 in a three-generation Han Chinese family from northern China, making it the first pathogenic PSEN2 mutation documented in any Asian population. Six family members across three generations developed dementia in their fifth decade and died in their sixth decade. The proband developed progressive memory impairment with inability to manage finances at age 43, and died at age 55 with autopsy-confirmed Alzheimer's disease. Grandparents, mother, and aunts were similarly affected. Sanger sequencing of seven family members confirmed perfect segregation: the mutation was present in all affected individuals and absent in all five unaffected relatives and 188 ethnically matched controls.

The Mechanism

Asparagine-141 sits in the first transmembrane domain (TM1) of presenilin-2, a region critical for the structural integrity of the catalytic cleft and for positioning APP substrate relative to the catalytic aspartates⁵⁵ a region critical for the structural integrity of the catalytic cleft and for positioning APP substrate relative to the catalytic aspartates
Structural studies of the γ-secretase complex show TM1 participates in a conformational gate that controls substrate access. Substituting the polar asparagine with the bulkier, aromatic tyrosine likely alters TM1 packing and shifts the geometry of APP cleavage. Functional studies of N141Y demonstrate the molecular fingerprint of pathogenic presenilin mutations: an elevated Aβ42/Aβ40 ratio (0.32 vs. 0.15 in wild-type), accumulation of toxic Aβ43 peptide, and a reduced Aβ37/Aβ42 ratio (0.17 vs. 0.44 in wild-type). This pattern — more long-chain, aggregation-prone Aβ peptides relative to the short-chain Aβ40 — is a hallmark of presenilin gain-of-dysfunction mutations.

Codon 141 appears to be a mutational hotspot in PSEN2: in addition to N141Y (Chinese Han families), N141I is associated with Volga German families (the most extensively characterized PSEN2 mutation), N141D has been reported in additional Chinese pedigrees, and N141S was recently validated functionally. The recurrence of mutations at this position across unrelated populations and ancestries supports the inference that asparagine-141 performs an essential, conserved structural role⁶⁶ supports the inference that asparagine-141 performs an essential, conserved structural role
Convergent evolution of disease mutations at the same position in independent families is itself moderate evidence of pathogenicity under ACMG criteria (PM5).

The Evidence

The Alzforum mutation database classifies N141Y as pathogenic based on ACMG/AMP criteria PS3, PM2, PM5, PP1, and PP3⁷⁷ classifies N141Y as pathogenic based on ACMG/AMP criteria PS3, PM2, PM5, PP1, and PP3
PS3: functional data showing altered Aβ profiles; PM2: absent from population databases; PM5: novel missense at same codon as known pathogenic N141I; PP1: segregation with disease in the family; PP3: in silico predictions support pathogenicity. The variant is absent from gnomAD (v2.1.1), consistent with a rare highly penetrant disease allele.

Cai et al. 2015⁸⁸ Cai et al. 2015
Mutations in presenilin 2 and its implications in Alzheimer's disease and other dementia-associated disorders. Clin Interv Aging, 2015 catalogued N141Y among pathogenic PSEN2 mutations in a systematic review, noting that the asparagine-to-tyrosine change at codon 141 likely alters the Aβ42/Aβ40 ratio by the same mechanism as N141I. A comprehensive overview of early-onset familial AD mutations in China by Qin et al. 2020⁹⁹ Qin et al. 2020
Gene mutations associated with EOFAD in China. Mol Genet Genomic Med, 2020 confirmed N141Y in this Chinese Han family and described the clinical course in detail.

A broader context is provided by the largest screening study to date, Lanoiselée et al. 2017¹⁰¹⁰ Lanoiselée et al. 2017
APP, PSEN1, and PSEN2 mutations in early-onset Alzheimer disease. PLoS Med, 2017, which showed that PSEN2 mutations are rare even among familial EOAD cases (only 4 distinct variants among 170 French families), and that PSEN2-associated AD has a mean onset around 53.9 years (range 45–69 years) — substantially later than PSEN1. Importantly, a systematic ACMG re-evaluation of all 63 reported PSEN2 variants by Holstege et al. 2021¹¹¹¹ Holstege et al. 2021
APP, PSEN1, and PSEN2 Variants in AD: Systematic Re-evaluation According to ACMG Guidelines. Front Aging Neurosci, 2021 found that only about 20% of previously reported pathogenic PSEN2 variants actually meet current criteria — N141Y is among those that do.

Practical Actions

Carrying the N141Y variant is a high-stakes finding. The mutation is associated with very high (though not absolute) lifetime risk of early-onset Alzheimer's disease. The primary practical implications are:

1. Genetic counselling and family communication: Autosomal dominant inheritance means each first-degree relative has a 50% chance of carrying the mutation. Proactive genetic counselling allows at-risk relatives to make informed decisions about predictive testing and life planning.

2. DIAN-TU clinical trial eligibility: Carriers of documented pathogenic PSEN2 mutations are eligible for enrollment in the Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU), which runs prevention trials in pre-symptomatic carriers beginning 10–15 years before expected symptom onset. This is the most direct access to potential disease-modifying treatment.

3. Biomarker monitoring and early diagnosis: Amyloid PET, CSF Aβ42/Aβ40 ratio, and plasma Aβ42/Aβ40 tests can detect the Alzheimer's biological cascade 10–20 years before symptom onset. In carrier families, this window allows structured monitoring, early diagnosis, and entry into trials.

4. Cognitive reserve building: While no lifestyle intervention prevents or cures genetic AD, higher cognitive reserve — built through education, cognitive engagement, and social activity throughout life — is associated with later symptom onset and slower progression¹²¹² higher cognitive reserve — built through education, cognitive engagement, and social activity throughout life — is associated with later symptom onset and slower progression
   Meta-analyses consistently show a correlation between cognitive reserve and age at AD symptom presentation, even in genetic cases, likely by increasing the amount of pathology the brain can tolerate before clinical expression.

Interactions

The primary disease-relevant interaction is the APOE ε4 allele. In PSEN2 N141I families (the best-studied codon 141 mutation), APOE ε4 is a significant modifier of age at onset, accelerating symptom presentation by several years. Yu et al. 2010¹³¹³ Yu et al. 2010
The N141I mutation in PSEN2: implications for the quintessential case of Alzheimer disease. Arch Neurol, 2010 identified APOE genotype as a significant covariate in nine N141I families. This interaction likely extends to N141Y given the structural similarity of the mutations. N141Y carriers who also carry APOE ε4 may have earlier onset than carriers without it.

In cells, presenilin-2 γ-secretase activity is partially compensated by presenilin-1 (PSEN1); the two presenilins are expressed at different levels and have partially overlapping substrates. However, because PSEN2 mutations appear to cause a partial loss-of-cleavage-function alongside a gain-of-Aβ42-production, this compensation is incomplete and disease results from heterozygous mutation alone.

Every time you eat, your small intestine releases hormones called incretins — principally GLP-1¹¹ GLP-1
glucagon-like peptide-1: a gut hormone that amplifies insulin secretion from the pancreas in response to a meal — that tell your pancreatic beta cells to release insulin in proportion to the meal's size. This variant near the CTRB1 and CTRB2 genes determines how efficiently that signal reaches your beta cells, with measurable consequences for both type 2 diabetes risk and how well DPP-4 inhibitor medications work for you.

The Mechanism

CTRB1 and CTRB2 encode chymotrypsinogen²² chymotrypsinogen
the inactive precursor of chymotrypsin, one of the most abundant digestive proteases in the small intestine, which is activated in the gut lumen to cleave dietary proteins. rs7202877 sits in an intergenic region between BCAR1 and the CTRB1/CTRB2 cluster on chromosome 16 and acts as an [expression quantitative trait locus (eQTL) | a DNA variant that controls how much of a nearby gene's mRNA is produced, without changing the protein sequence itself] for both CTRB1 and CTRB2. The G allele increases CTRB1 and CTRB2 expression, raising fecal chymotrypsin activity. This elevated chymotrypsin activity appears to enhance beta-cell sensitivity to GLP-1 signaling — the precise molecular link is not yet fully resolved, but the pharmacological consequence is clear.

The Evidence

The landmark 2013 study³³ landmark 2013 study
't Hart et al. The CTRB1/2 locus affects diabetes susceptibility and treatment via the incretin pathway. Diabetes, 2013 by 't Hart et al. in nondiabetic Caucasian individuals and treated T2D cohorts demonstrated that rs7202877 produces a 30–40% difference in GLP-1-stimulated insulin secretion between genotype groups. In a separate cohort of 527 T2D patients on DPP-4 inhibitors, G-allele carriers achieved an absolute 0.51 ± 0.16% (5.6 ± 1.7 mmol/mol) smaller reduction in HbA1c compared to T homozygotes — yet showed no difference in response to GLP-1 receptor agonists such as liraglutide. This treatment paradox reflects the same biology: G-allele carriers already benefit from enhanced endogenous incretin sensitivity and have less remaining incretin-pathway reserve to capture with a DPP-4 inhibitor.

Harder et al. (J Clin Endocrinol Metab, 2013)⁴⁴ Harder et al. (J Clin Endocrinol Metab, 2013)
Harder MN et al. Type 2 diabetes risk alleles near BCAR1 and in ANK1 associate with decreased β-cell function whereas risk alleles near ANKRD55 and GRB14 associate with decreased insulin sensitivity. J Clin Endocrinol Metab, 2013 studied 5,739 Danish individuals and confirmed the T-allele mechanism: carriers had a significantly decreased disposition index⁵⁵ disposition index
a measure of pancreatic beta-cell compensatory capacity that accounts for both insulin sensitivity and insulin secretion (p = 0.02), locating the diabetogenic effect squarely in beta-cell function rather than in peripheral insulin resistance.

A case-control replication in 1,961 Chinese Han participants (Kazakova et al., Acta Biochim Pol, 2018)⁶⁶ 1,961 Chinese Han participants (Kazakova et al., Acta Biochim Pol, 2018)
Kazakova EV et al. Association between RBMS1 gene rs7593730 and BCAR1 gene rs7202877 and type 2 diabetes mellitus in the Chinese Han population. Acta Biochim Pol, 2018 found GG homozygotes had a dramatically lower T2DM risk compared to TT carriers (OR 0.44, 95% CI 0.20–0.96, p = 0.038), with the G allele also correlating with lower total cholesterol and LDL-C levels.

Practical Actions

For the approximately 76% of people with the TT genotype, this variant has no special dietary or supplement implication — it represents the population baseline. Where it matters most is for people already prescribed or considering a DPP-4 inhibitor: TT carriers tend to respond better to these drugs, while G carriers may benefit more from alternative incretin-pathway approaches such as GLP-1 receptor agonists. If you have T2D or prediabetes and are a G allele carrier, discuss with your prescriber whether a GLP-1 receptor agonist rather than a DPP-4 inhibitor is a better fit for your pharmacogenetics.

Interactions

This variant acts in the same incretin pathway as TCF7L2 rs7903146 (the strongest common genetic predictor of T2D) and KCNJ11 rs5219 (a beta-cell ATP-sensitive potassium channel variant). Carriers of risk alleles at multiple beta-cell loci accumulate additive deficits in insulin secretion capacity. The CTRB1/2 pathway is distinct from TCF7L2's Wnt-mediated transcription and from KCNJ11's ion channel mechanism, meaning all three can independently compound. See compound action proposals in harvesting notes.

MTHFD2 (methylenetetrahydrofolate dehydrogenase 2) is the mitochondrial isoform of the folate-processing enzyme family. While MTHFD1 handles the same reactions in the cytoplasm, MTHFD2 operates in the mitochondrial matrix¹¹ mitochondrial matrix
The innermost compartment of the mitochondrion, where MTHFD2 oxidizes 5,10-methylene-THF to produce one-carbon units exported to the cytoplasm, converting 5,10-methyleneTHF to 10-formylTHF and feeding one-carbon units into the purine synthesis and methylation cycles. The gene has an unusual expression pattern: it is highly expressed during embryonic development, nearly silenced in most adult tissues, and then re-expressed at high levels in the vast majority of human cancers — earning it the label of a "developmental gene hijacked by cancer."

The rs828903 variant (A>G, intronic, chr2:74,209,593) sits within MTHFD2's coding sequence at the intron 6 splice region (c.563-348A>G). It does not alter the protein directly but may influence pre-mRNA splicing efficiency or intron retention patterns, potentially modulating MTHFD2 expression levels. The G allele has been studied in the context of folate pathway function, neural tube defect risk, and folate receptor autoantibody production.

The Mechanism

MTHFD2 catalyzes two sequential reactions in the mitochondria: the NAD(P)+- dependent oxidation of 5,10-methyleneTHF to 5,10-methenylTHF (dehydrogenase activity), followed by hydrolysis to 10-formylTHF (cyclohydrolase activity). The 10-formylTHF produced is the primary mitochondrial one-carbon donor, used to formylate mitochondrial methionyl-tRNA²² formylate mitochondrial methionyl-tRNA
Formylation of the initiator met-tRNA is required to start mitochondrial protein translation; MTHFD2 is therefore essential for mitochondrial ribosome function and to export one-carbon units to the cytoplasm for purine synthesis and methylation reactions.

The intronic rs828903 G allele may subtly alter splicing of MTHFD2 pre-mRNA. When MTHFD2 activity is reduced, mitochondrial one-carbon export to the cytoplasm decreases, constraining de novo purine synthesis and potentially reducing the folate available for homocysteine remethylation. Downstream consequences include elevated homocysteine and impaired rapid-cell-division processes — exactly the conditions that compromise early embryonic development and neural tube closure.

A separate mechanism connects MTHFD2 to the immune system: elevated MTHFD2 activity in endothelial cells under oxidized phospholipid stress³³ oxidized phospholipid stress
Oxidized phospholipids accumulate in atherosclerotic plaques and signal endothelial activation; MTHFD2 re-wires amino acid metabolism in response drives serine-glycine metabolism and nucleotide release, linking MTHFD2 function to cardiovascular inflammation.

The Evidence

Shaw et al. (2009)⁴⁴ Shaw et al. (2009)
Shaw GM et al. 118 SNPs of folate-related genes and risks of spina bifida and conotruncal heart defects. BMC Med Genet, 2009 genotyped 118 SNPs across folate pathway genes in 259 spina bifida cases, 214 conotruncal heart defect cases, and 359 controls from a California population registry. MTHFD2 variants including rs828903 showed protective odds ratios of approximately 0.6 (95% CI: 0.4–0.9) for spina bifida — an unexpected direction suggesting that the variant allele may alter folate flux in ways that reduce rather than increase neural tube defect risk in this study population. The authors noted widespread linkage disequilibrium among MTHFD2 SNPs, making independent effect estimation challenging.

Dong et al. (2018)⁵⁵ Dong et al. (2018)
Dong Y et al. Gene variants in the folate pathway are associated with increased levels of folate receptor autoantibodies. Birth Defects Res, 2018 found in 302 pregnant Chinese women that the rs828903 GG genotype was associated with significantly elevated folate receptor IgM autoantibody levels (β = 0.60, 95% CI 0.10–1.10). Folate receptor (FR) autoantibodies block folate uptake into cells⁶⁶ block folate uptake into cells
FR autoantibodies bind the folate receptor and sterically obstruct folate binding, reducing cellular folate uptake even when dietary folate is adequate and have been proposed as a mechanism for folate-related embryonic risk that operates independently of dietary folate intake. A person with the GG genotype and elevated FR autoantibodies may have functional folate insufficiency despite normal serum folate.

Hitzel et al. (2018)⁷⁷ Hitzel et al. (2018)
Hitzel J et al. Oxidized phospholipids regulate amino acid metabolism through MTHFD2. Nat Commun, 2018 showed that MTHFD2 controls serine-glycine-purine metabolism in endothelial cells in response to atherogenic oxidized phospholipids, and that SNPs within this MTHFD2-controlled metabolic cluster associate with coronary artery disease — adding a cardiovascular dimension to MTHFD2 genetic variation.

From a cancer perspective, Ramos et al. (2024)⁸⁸ Ramos et al. (2024)
Ramos L et al. Targeting MTHFD2 to exploit cancer-specific metabolism and the DNA damage response. Cancer Res, 2024 review MTHFD2 as re-expressed across numerous cancer types, correlating with poorer survival and representing an emerging therapeutic target. The cancer re-expression pattern reflects MTHFD2's embryonic developmental role — both cancer cells and embryonic cells require maximal one-carbon output for rapid division.

Practical Actions

For individuals with the GG genotype, the main concern is functional folate availability: the combination of potential MTHFD2 splicing effects and the risk of elevated folate receptor autoantibodies may reduce effective folate delivery even when dietary intake is adequate. Methylfolate supplementation and monitoring of functional folate status are the primary actions.

The variant also intersects with immune function via MTHFD2's role in T cell metabolism — MTHFD2 activity shapes the balance between inflammatory effector T cells and regulatory T cells, suggesting a connection between MTHFD2 function and autoimmune risk.

Interactions

MTHFD2 and MTHFD1 (rs2236224 / R653Q) catalyze the same reactions in different compartments — mitochondria vs cytoplasm — but supply the same cytoplasmic one-carbon pool. Carriers of MTHFD2 intronic variants alongside MTHFD1 R653Q may face compounded reduction in cytoplasmic one-carbon availability, amplifying the demand on the folate cycle. MTHFR C677T (rs1801133) further constrains this pathway by reducing conversion of folate to methylfolate.

Folate receptor autoantibodies associated with the GG genotype interact with dietary folate intake: the autoantibody-related block in folate uptake is most consequential when dietary folate is marginal. Higher methylfolate intake can partially overcome receptor-level blockade by saturating available receptors.